Cargando…
Diabetic macular edema treated with intravitreal aflibercept injection after treatment with other anti-VEGF agents (SWAP-TWO study): 6-month interim analysis
BACKGROUND: Diabetic macular edema (DME) is an important cause of vision loss and despite the anatomical and functional improvement achieved with treatment, there are reports of persistent DME regardless of continuous anti-VEGF therapy. The purpose of this study is to examine the effect of patients...
Autores principales: | Babiuch, Amy S., Conti, Thais F., Conti, Felipe F., Silva, Fabiana Q., Rachitskaya, Aleksandra, Yuan, Alex, Singh, Rishi P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6647124/ https://www.ncbi.nlm.nih.gov/pubmed/31367468 http://dx.doi.org/10.1186/s40942-019-0167-x |
Ejemplares similares
-
Effect of intravitreal aflibercept on recalcitrant diabetic macular edema
por: Klein, Kendra A., et al.
Publicado: (2017) -
Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema
por: Fouda, Sameh Mosaad, et al.
Publicado: (2017) -
Randomized clinical trial comparing intravitreal aflibercept combined with subthreshold laser to intravitreal aflibercept monotherapy for diabetic macular edema
por: Tatsumi, Tomoaki, et al.
Publicado: (2022) -
Intravitreal ziv-aflibercept for macular edema following retinal vein occlusion
por: Paulose, Remya, et al.
Publicado: (2016) -
Comparisons of Efficacy of Intravitreal Aflibercept and Ranibizumab in Eyes with Diabetic Macular Edema
por: Shimizu, Norihiro, et al.
Publicado: (2017)